)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Wockhardt
Wockhardt (WOCKPHARMA) investor relations material
Wockhardt Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary2 Nov, 2026
Executive summary
Q2 and H1 results for the period ended September 30, 2026, were approved by the Board; statutory auditors issued limited review conclusions on the standalone and consolidated results.
Consolidated Q2 revenue from operations was Rs 969 crore and H1 revenue was Rs 1,898 crore; standalone H1 net profit was Rs 207 crore.
Financial highlights
Consolidated Q2 revenue from operations was Rs 969 crore vs Rs 782 crore YoY; H1 revenue was Rs 1,898 crore vs Rs 1,520 crore.
Consolidated Q2 PBT before exceptional items was Rs 73 crore vs Rs 91 crore YoY; H1 PBT was Rs 189 crore vs a reported loss of Rs 18 crore in H1 FY26.
Standalone Q2 revenue from operations was Rs 580 crore vs Rs 380 crore YoY; H1 revenue was Rs 1,141 crore vs Rs 793 crore.
Standalone H1 net profit was Rs 207 crore vs Rs 123 crore YoY; Q2 net profit was Rs 100 crore vs Rs 54 crore.
Segment performance
Operations are exclusively in the pharmaceutical business segment, on both standalone and consolidated bases.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Wockhardt
- Sales rose 33% as exports, R&D and expansion advanced, alongside higher commitments and debt.WOCKPHARMA
Q4 96/97 - Sales grew 36% as acquisitions, exports and R&D drove the expansion agenda.WOCKPHARMAQ4 97/98
- Demerger and global expansion accompany 42% annualized operating-income growth.WOCKPHARMAQ4 1999
- Sales grew 34% as exports, R&D and new-product launches expanded.WOCKPHARMAQ4 2000
- Sales rose 16%, profit 43%, and operating margin reached 20% amid export and biotech expansion.WOCKPHARMAQ4 2001
- Exports and R&D advanced as domestic pharma growth slowed.WOCKPHARMAQ4 2002
- International expansion drove 21% revenue growth as overseas sales reached 57% of total.WOCKPHARMAQ4 2003
- FY04 sales rose 32%, while net profit grew 50% amid global expansion.WOCKPHARMAQ4 2004
- FY 2005 growth combined stronger US and biotech results with a global expansion push.WOCKPHARMAQ4 2005
Next Wockhardt earnings date
Q3 26/2714 Feb, 2027
Wockhardt
Next Wockhardt earnings date
Q3 26/2714 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Wockhardt Limited is a pharmaceutical and biotechnology company engaged in the research, development, manufacturing, and marketing of pharmaceutical formulations, biopharmaceuticals, and active pharmaceutical ingredients (APIs). The company operates across therapeutic areas including anti-infectives, cardiology, neurology, and diabetes care. It has manufacturing and research facilities that comply with international regulatory standards and serves both domestic and global markets. The company is headquartered in Mumbai, India, and its shares are listed on the BSE.